Cipla has beein issued six inspectional observations by the US Food and Drug Administration (USFDA) following a recent inspection of its manufacturing facility in Patalganga, Maharashtra, India, according to a Thursday filing to the Indian stock exchanges.

The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4. On completion of the inspection, Cipla received six inspectional observations in Form 483.

Cipla said it would address within the stipulated time.